No Pathogen Mutation or Resistance Reported

BACO is an “equal opportunity” antimicrobial, in that it steps up antipathogenic activity against a broad spectrum of disease-causing microorganisms including viruses, bacteria, fungi, yeasts, and cancers. Development of resistance to BACO would be extremely rare because an organism would have to undergo simultaneous mutations in every critical function within a single generation to escape the positive influences.

Pathogens cannot mutate quickly enough to avoid BACO’s antipathogenic effects. Even if they do mutate, BACO will destroy any mutated microbes. Spontaneous mutation of microbes is rare, occurring in only one per 100,000 divisions, therefore the probability of multiple dependent mutations occurring in the same generation is statistically unlikely.

BACO is equally effective against new, more virulent strains of drug-resistant and previously-mutated pathogens. Extensive tests with BACO against difficult-to-control microbials, such as Staph and E-Coli have shown that even the so-called Staph “Super Bug” can easily be controlled by supplying BACO in normal dosing, either prior to or after a patient becomes infected, and misting the affected areas. As a spray or aqueous bath, BACO penetrates microbial film which harbors Staph on hospital instruments and devices, destroying these infectious pathogens on contact.